ABUS Arbutus Biopharma Corporation - Common Stock
NASDAQ · Biotechnology · SEC EDGAR पर देखें ↗ बंद अक्ट 2, 2026 10-K/10-Q अग 12, 2026ABUS स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
ABUS स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
बार ग्रैन्युलैरिटी चयनित अवधि के अनुसार अनुकूलित होती है — बार के लिए ओपन/हाई/लो/क्लोज देखने के लिए चार्ट पर होवर करें।
| एक्स-डेट | स्प्लिट | प्रकार |
|---|---|---|
| 4 नवमबर 2010 | 1-for-5 | रिवर्स |
Arbutus Biopharma Corporation - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
| मेट्रिक | 5Y रुझान | ABUS | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| P/E (TTM) | 5.65Y औसत ≈-10.5 | ≈-10.5 | · | · | |
| P/S (TTM) | 4.85Y औसत ≈50.1 | ≈50.1 | 10.3 | अल्पमूल्यित | |
| P/B (MRQ) | 3.45Y औसत ≈5.7 | ≈5.7 | 3.7 | उचित मूल्य | |
| Price / FCF (मूल्य / FCF) | -22.15Y औसत ≈-11.3 | ≈-11.3 | · | · | |
| Price / Cash Flow (मूल्य / नकदी प्रवाह) | -22.15Y औसत ≈-11.3 | ≈-11.3 | · | · | |
| Price / Tangible Book (मूल्य / मूर्त पुस्तक) | 11.45Y औसत ≈5.7 | ≈5.7 | · | · |
सहकर्मी माध्यिका को प्रति मीट्रिक मानकीकृत आधार पर गणना की जाती है और यह हमेशा इस स्टॉक के लिए दिखाए गए TTM/MRQ आधार से मेल नहीं खा सकती है।
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
| मेट्रिक | 5Y रुझान | ABUS | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| परिचालन मार्जिन (TTM) | 82.0%5Y औसत ≈-555.0% | ≈-555.0% | -588.2% | अनुरूप | |
| EBITDA Margin (EBITDA मार्जिन) | -271.0%5Y औसत ≈-555.0% | ≈-555.0% | -588.2% | अनुरूप | |
| शुद्ध लाभ मार्जिन (TTM) | 84.2%5Y औसत ≈-528.9% | ≈-528.9% | -507.2% | अनुरूप | |
| ROA (TTM) | 81.1%5Y औसत ≈-40.5% | ≈-40.5% | -29.6% | अनुरूप | |
| ROE (TTM) | 89.6%5Y औसत ≈-55.0% | ≈-55.0% | -42.0% | अनुरूप |
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
| मेट्रिक | 5Y रुझान | ABUS | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| वर्तमान अनुपात (MRQ) | 81.45Y औसत ≈9.7 | ≈9.7 | 9.6 | मजबूत तरलता | |
| Quick Ratio (त्वरित अनुपात) | 15.55Y औसत ≈9.5 | ≈9.5 | 6.6 | अनुरूप |
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
| मेट्रिक | 5Y रुझान | ABUS | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Revenue YoY (राजस्व YoY) | 128.2%5Y औसत ≈64.5% | ≈64.5% | · | · | |
| Revenue CAGR 3Y (राजस्व CAGR 3Y) | -28.8%5Y औसत ≈-2.8% | ≈-2.8% | · | · | |
| Revenue CAGR 5Y (राजस्व CAGR 5Y) | 15.3% | · | · | · |
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
| मेट्रिक | 5Y रुझान | ABUS | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Asset Turnover (परिसंपत्ति टर्नओवर) | 0.15Y औसत ≈0.1 | ≈0.1 | 0.2 | कमजोर | |
| Receivables Turnover (प्राप्य टर्नओवर) | 7.35Y औसत ≈13.3 | ≈13.3 | · | · | |
| Revenue / Employee (राजस्व / कर्मचारी (रिपोर्ट की गई हेडकाउंट, यफाइनांस)। व्युत्पन्न — संग्रहीत SEC-XBRL अवधारणा नहीं है।) | ≈$741.2K | · | · | · |
मान · ≈ 5Y औसत · उद्योग माध्य · माध्य के सापेक्ष निर्णय
Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | रिपोर्ट | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|---|
| 30 जून 2026 | अग 4, 2026 | $-0.03 | $-0.02 | -47.1% |
| 31 मार्च 2026 | मई 12, 2026 | $1.19 | $-0.03 | 3988.9% |
| 31 दिसमबर 2025 | $-0.02 | $-0.04 | 44.0% | |
| 30 सितमबर 2025 | $-0.04 | $-0.03 | -26.6% | |
| 30 जून 2025 | $0.01 | $-0.05 | 120.6% | |
| 31 मार्च 2025 | $-0.13 | $-0.11 | -23.2% | |
| 31 दिसमबर 2024 | $-0.07 | $-0.08 | 14.2% |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
बैलेंस शीट
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
नकदी प्रवाह
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
लाभप्रदता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
दक्षता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
प्रति शेयर
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.40 | $0.51 | $0.62 | $0.87 | $1.17 | $1.14 | · | $3.61 | $3.31 | $3.70 | · | |
| Revenue / Share | $0.07 | $0.03 | $0.11 | $0.26 | $0.10 | · | · | $0.11 | $0.20 | $0.03 | · | |
| Cash Flow / Share | $-0.21 | $-0.35 | $-0.52 | $-0.23 | $-0.64 | · | · | $-1.23 | $-0.89 | $-1.09 | · | |
| Cash / Share | $0.09 | $0.19 | $0.15 | $0.20 | $0.75 | $0.58 | · | $0.67 | $0.99 | $0.43 | · | |
| EPS (TTM) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-1.32 | $-1.21 | $-1.56 | $-7.24 | $-1.38 |
विकास दरें
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
आय विवरण
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | · | 191,778,950 | 191,551,282 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | · | 191,778,950 | 192,399,733 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
बैलेंस शीट
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
नकदी प्रवाह
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
लाभप्रदता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
दक्षता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
प्रति शेयर
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.31 | $1.32 | · | $0.40 | $0.43 | $0.41 | · | $0.56 | $0.65 | $0.64 | · | $0.71 | $0.81 | $0.87 | · | $0.95 | |
| Revenue / Share | $0.01 | $0.92 | · | $0.00 | $0.06 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.03 | $0.03 | $0.04 | · | $0.04 | |
| Cash Flow / Share | · | $-0.04 | · | · | · | $-0.07 | · | · | · | $-0.11 | · | · | · | $-0.17 | · | · | |
| Cash / Share | $0.10 | $0.12 | · | $0.12 | $0.20 | $0.19 | · | $0.17 | $0.33 | $0.24 | · | $0.10 | $0.16 | $0.25 | · | $0.16 | |
| EPS (TTM) | $0.79 | $0.83 | · | $-0.23 | $-0.29 | $-0.41 | · | $-0.43 | $-0.45 | $-0.44 | · | $-0.45 | $-0.45 | $-0.45 | · | $-0.48 |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $182M | $191M | · | $15M | $15M | $6M | · | $7M | $10M | $13M | · | $22M | $24M | $33M | · | $36M | |
| Net Income TTM | $153M | $161M | · | $-42M | $-54M | $-77M | · | $-77M | $-77M | $-74M | · | $-75M | $-73M | $-70M | · | $-69M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 6.1 | 5.4 | · | -19.7 | -10.7 | -8.5 | · | -9.0 | -6.9 | -5.9 | · | -4.5 | -5.1 | -6.7 | · | -4.0 | |
| P/S | 5.2 | 4.6 | · | 59.7 | 38.4 | 104.4 | · | 108.2 | 58.0 | 35.8 | · | 15.3 | 16.3 | 15.1 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| Earnings Yield | 16.5% | 18.4% | · | -5.1% | -9.4% | -11.8% | · | -11.2% | -14.6% | -17.1% | · | -22.2% | -19.6% | -14.8% | · | -25.1% |
सबसे हाल की अवधि बाईं ओर · शून्य मान इस प्रकार दिखाए गए हैं ·
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| राजस्व | $14M | $6M | $18M | $39M | $11M |
| परिचालन मार्जिन % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| शुद्ध आय | $-34M | $-70M | $-73M | $-69M | $-76M |
| तनुकरणित EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| त्वरित अनुपात | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $-40M | $-65M | $-87M | $-36M | $-68M |
संस्थागत मालिक (13F) 187 फाइलर्स · $719.6M कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 35 (+3 पिछली तिमाही की तुलना में) | 23 (-8 पिछली तिमाही की तुलना में) | 62 (+13 पिछली तिमाही की तुलना में) | 42 (-10 पिछली तिमाही की तुलना में) | +466K |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| Two Seas Capital LP | $91658798 | 19095583 | 12.74% | शेयर |
| MORGAN STANLEY | $84951868 | 17698305 | 11.81% | शेयर |
| Whitefort Capital Management, LP | $75812453 | 15794261 | 10.54% | शेयर |
| BlackRock, Inc. | $66077140 | 13766071 | 9.18% | शेयर |
| VANGUARD GROUP INC | $44456122 | 9242437 | 6.18% | शेयर |
| STATE STREET CORP | $37772059 | 7869179 | 5.25% | शेयर |
| Rubric Capital Management LP | $36158098 | 7532937 | 5.03% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $33651259 | 7010679 | 4.68% | शेयर |
| BARCLAYS PLC | $20197987 | 4207914 | 2.81% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $19769043 | 4117691 | 2.75% | शेयर |
| GOLDMAN SACHS GROUP INC | $16832650 | 3506802 | 2.34% | शेयर |
| BANK OF AMERICA CORP /DE/ | $12701745 | 2646197 | 1.77% | शेयर |
| BlackBarn Capital Partners LP | $12000000 | 2500000 | 1.67% | शेयर |
| Legal & General Group Plc | $11837409 | 2466127 | 1.65% | शेयर |
| Woodline Partners LP | $10952909 | 2281856 | 1.52% | शेयर |
| Jefferies Financial Group Inc. | $8216026 | 1711672 | 1.14% | शेयर |
| NOMURA HOLDINGS INC | $7857989 | 1637081 | 1.09% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7398998 | 1541458 | 1.03% | शेयर |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6869846 | 1431218 | 0.95% | शेयर |
| NORTHERN TRUST CORP | $6811315 | 1419024 | 0.95% | शेयर |
| OSAIC HOLDINGS, INC. | $6469756 | 1347866 | 0.90% | शेयर |
| ADAR1 Capital Management, LLC | $6087106 | 1268147 | 0.85% | शेयर |
| Deltroit Asset Management (UK) LLP | $5760000 | 1200000 | 0.80% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $5449738 | 1135362 | 0.76% | शेयर |
| CITIGROUP INC | $4220338 | 879237 | 0.59% | शेयर |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3771945 | 838210 | 0.52% | शेयर |
| BANK OF MONTREAL /CAN/ | $3734102 | 777938 | 0.52% | शेयर |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3123360 | 650700 | 0.43% | शेयर |
| MACKENZIE FINANCIAL CORP | $2946269 | 613806 | 0.41% | शेयर |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2889638 | 602008 | 0.40% | शेयर |
| Western Standard LLC | $2605378 | 542787 | 0.36% | शेयर |
| Rangeley Capital, LLC | $2400000 | 500000 | 0.33% | शेयर |
| Nuveen, LLC | $2383723 | 496609 | 0.33% | शेयर |
| Man Group plc | $2272642 | 473467 | 0.32% | शेयर |
| WELLINGTON MANAGEMENT GROUP LLP | $2215900 | 461646 | 0.31% | शेयर |
| Bank of New York Mellon Corp | $2179752 | 454115 | 0.30% | शेयर |
| CenterBook Partners LP | $2136725 | 445151 | 0.30% | शेयर |
| Freestone Capital Holdings, LLC | $2124000 | 442500 | 0.30% | शेयर |
| CITADEL ADVISORS LLC | $1942541 | 404696 | 0.27% | शेयर |
| KENNEDY CAPITAL MANAGEMENT LLC | $1849430 | 385298 | 0.26% | शेयर |
| D. E. Shaw & Co., Inc. | $1832942 | 381863 | 0.25% | शेयर |
| Swiss National Bank | $1375200 | 286500 | 0.19% | शेयर |
| Ledgewood Wealth Advisors, LLC | $1336493 | 278436 | 0.19% | शेयर |
| FMR LLC | $1282503 | 267188 | 0.18% | शेयर |
| Susquehanna Portfolio Strategies, LLC | $1265688 | 263685 | 0.18% | शेयर |
| Carrera Capital Advisors | $1234402 | 257167 | 0.17% | शेयर |
| Quinn Opportunity Partners LLC | $1225027 | 255214 | 0.17% | शेयर |
| Invesco Ltd. | $1204353 | 250907 | 0.17% | शेयर |
| UBS Group AG | $1196198 | 249208 | 0.17% | शेयर |
| STATE OF WISCONSIN INVESTMENT BOARD | $1161682 | 242017 | 0.16% | शेयर |
कार्यकर्ता और 5%+ मालिक 8 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 फाइलिंग | 28 अप्रैल 2026 | 8.00% | संशोधन | · | SEC |
| Roivant Sciences Ltd. ×14 फाइलिंग | 25 फ़रवरी 2025 | 20.50% | संशोधन | · | SEC |
| Patrick Machado ×4 फाइलिंग | 17 जुलाई 2019 | · | प्रारंभिक फाइलिंग | · | SEC |
| Dr. Andrew Lo ×5 फाइलिंग | 17 जुलाई 2019 | · | प्रारंभिक फाइलिंग | · | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 फाइलिंग | 12 जुलाई 2019 | · | प्रारंभिक फाइलिंग | · | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 फाइलिंग | 12 जुलाई 2019 | · | प्रारंभिक फाइलिंग | · | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 फाइलिंग | 12 जुलाई 2019 | · | प्रारंभिक फाइलिंग | · | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 फाइलिंग | 12 जुलाई 2019 | · | प्रारंभिक फाइलिंग | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
कंपनी के अंदरूनी सूत्र 35 इनसाइडर्स · 17 अधिकारी · 19 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Lindsay Androski | President and CEO | 18 सितमबर 2026 M | 72337 | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Interim President & CEO | 14 फ़रवरी 2025 A | 1658003 | 0 | 0 | $0 |
| William H. Collier | President and CEO | 1 फ़रवरी 2023 A | 216500 | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 1 मार्च 2019 A | 341396 | 0 | 0 | $0 |
| Tuan Nguyen | Chief Financial Officer | 18 सितमबर 2026 M | 159963 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 14 फ़रवरी 2025 A | 249824 | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 24 मार्च 2017 A | · | 0 | 0 | $0 |
| Karen Sims | Chief Medical Officer | 14 फ़रवरी 2025 A | 155494 | 0 | 0 | $0 |
| Christopher J. Naftzger | General Counsel and CCO | 14 फ़रवरी 2025 A | 140544 | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 1 फ़रवरी 2024 A | 1485121 | 0 | 0 | $0 |
| Elizabeth Howard | EVP, GC, Compliance | 1 फ़रवरी 2023 A | 86024 | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 20 जनवरी 2022 A | · | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 11 दिसमबर 2018 A | · | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 16 अप्रैल 2018 A | · | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 24 मार्च 2017 A | · | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 16 अगस्त 2016 M | 42097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 15 मार्च 2016 A | · | 0 | 0 | $0 |
| Roger Sawhney | निदेशक | 18 सितमबर 2026 M | 30825 | 0 | 0 | $0 |
| Robert A Beardsley | निदेशक | 18 सितमबर 2026 M | 32276 | 0 | 0 | $0 |
| Anuj Hasija | निदेशक | 18 मार्च 2025 A | · | 0 | 0 | $0 |
| Keith S Manchester | निदेशक | 14 अगस्त 2024 M | 46069 | 0 | 0 | $0 |
| Melissa Rewolinski | निदेशक | 23 मई 2024 A | · | 0 | 0 | $0 |
| Frank Torti | निदेशक | 23 मई 2024 A | · | 0 | 0 | $0 |
| James R Meyers | निदेशक | 23 मई 2024 A | · | 0 | 0 | $0 |
| Daniel D Burgess | निदेशक | 23 मई 2024 A | · | 0 | 0 | $0 |
| Richard C Henriques JR | निदेशक | 23 मई 2024 A | 1000 | 0 | 0 | $0 |
| Tram Tran | निदेशक | 25 मई 2022 A | · | 0 | 0 | $0 |
| Andrew Cheng | निदेशक | 3 जून 2021 A | · | 0 | 0 | $0 |
| Myrtle S Potter | निदेशक | 17 अगस्त 2019 A | · | 0 | 0 | $0 |
| Vivek Ramaswamy | निदेशक | 19 जून 2018 A | · | 0 | 0 | $0 |
| Herbert J Conrad | निदेशक | 19 जून 2018 A | · | 0 | 0 | $0 |
| Frank Karbe | निदेशक | 21 जून 2017 A | · | 0 | 0 | $0 |
| Roivant Sciences Ltd. | 10% मालिक | 18 अक्टूबर 2021 C | 38847462 | 0 | 0 | $0 |
| Andrew Lo | 10% मालिक | 12 जनवरी 2018 P | · | 0 | 0 | $0 |
| Patrick Machado | 10% मालिक | 12 जनवरी 2018 P | · | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
ईटीएफ स्वामित्व 26 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.68% | 72962 NS | 31 जुलाई 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0.62% | 521191 NS | 31 जुलाई 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.47% | 23611 SH | 2 अक्टूबर 2026 | दैनिक |
| IWC · iShares Trust | 0.19% | 545721 SH | 11 सितमबर 2026 | दैनिक |
| LABU · Direxion Shares ETF Trust | 0.11% | 124896 NS | 31 जुलाई 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.06% | 14124 SH | 2 अक्टूबर 2026 | दैनिक |
| IBB · iShares Trust | 0.06% | 1201130 SH | 11 सितमबर 2026 | दैनिक |
| IWO · iShares Trust | 0.05% | 1506889 SH | 11 सितमबर 2026 | दैनिक |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.05% | 172487 SH | 19 अगस्त 2026 | दैनिक |
| PWS · Pacer Funds Trust | 0.03% | 1706 NS | 31 जुलाई 2026 | N-PORT |
| IWM · iShares Trust | 0.03% | 4035105 SH | 11 सितमबर 2026 | दैनिक |
| RSSL · Global X Funds | 0.02% | 76843 NS | 31 जुलाई 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 120110 SH | 2 अक्टूबर 2026 | दैनिक |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 925044 SH | 19 अगस्त 2026 | दैनिक |
| ISCG · iShares Trust | 0.01% | 24707 SH | 11 सितमबर 2026 | दैनिक |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 1810587 SH | 19 अगस्त 2026 | दैनिक |
| VHT · VANGUARD WORLD FUND | 0.01% | 430244 SH | 19 अगस्त 2026 | दैनिक |
| WSML · iShares Trust | 0.01% | 11624 SH | 9 सितमबर 2026 | दैनिक |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 66333 NS | 31 जुलाई 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 265986 SH | 11 सितमबर 2026 | दैनिक |
| IWV · iShares Trust | 0.00% | 49783 SH | 9 सितमबर 2026 | दैनिक |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 5034547 SH | 19 अगस्त 2026 | दैनिक |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 13683 SH | 19 अगस्त 2026 | दैनिक |
| ISCB · iShares Trust | · | 6673 SH | 11 सितमबर 2026 | दैनिक |
| ISCV · iShares Trust | · | 13314 SH | 11 सितमबर 2026 | दैनिक |
| SMMV · iShares Trust | · | 60845 SH | 1 सितमबर 2026 | दैनिक |
ABUS विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
12-महीने का मूल्य लक्ष्य
1 विश्लेषक · 2026-09-28माध्य लक्ष्य $5.39 +21.0%
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
वित्तीय वर्ष के आधार पर, प्रत्येक कंपनी के पिछले वित्तीय वर्ष के अंत के बंद भाव के अनुसार कीमतें।
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर फुल फंडामेंटल्स में किसी भी पंक्ति के बगल में + पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।